Tetrahydrozoline Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

DRUG NAME: Tetrahydrozoline

Therapeutic Class: Sympathomimetic (α-adrenergic agonist)

Subclass: Ocular and nasal decongestant

Speciality: Ophthalmology

Schedule (India): Not under Schedule H/X (OTC availability; clinical caution advised)

Route(s): Ophthalmic, Intranasal (topical use only)

Formulations Available in India:
• Ophthalmic drops: 0.05% w/v (tetrahydrozoline hydrochloride)
• Nasal drops: 0.05% w/v

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India):

1. Ocular Congestion (Allergic/Irritative Conjunctivitis)

Parameter	Recommendation
Starting dose	1 drop into affected eye(s)
Titration	Not applicable
Usual maintenance dose	1–2 drops up to 4 times daily
Maximum dose	2 drops per eye, 4 times daily
Maximum duration	72 hours of continuous use
Clinical note	Prolonged use causes rebound hyperaemia and tolerance

2. Nasal Congestion (Temporary Relief)

Parameter	Recommendation
Starting dose	2 drops in each nostril
Titration	Not applicable
Usual maintenance dose	2–4 drops in each nostril every 6–8 hours
Maximum dose	4 drops per nostril, 3–4 times daily
Maximum duration	Not more than 5 consecutive days
Clinical note	Avoid in chronic rhinitis; risk of rhinitis medicamentosa

Secondary Indications – Adults Only (Off-label):

None documented in Indian practice.

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India):

1. Ocular Congestion:

Age Group	Dose	Frequency	Maximum Duration
<6 years	Not recommended	—	—
≥6 years	1 drop in each eye	Up to 4 times daily	72 hours

2. Nasal Congestion:

Age Group	Formulation	Dose	Frequency	Maximum Duration
<2 years	Not recommended except under specialist supervision	—	—	—
2–6 years	0.025% solution	1–2 drops per nostril	Every 8–10 hours	3–5 days
>6 years	0.05% solution	1–2 drops per nostril	Every 8 hours	3–5 days

Note: 0.025% paediatric formulation may have limited availability in India.

Safety Monitoring:
• Monitor for sedation, bradycardia, and CNS depression (risk of systemic absorption)
• Not recommended below 2 years without specialist supervision
• Accidental ingestion can cause severe toxicity — ensure safe storage

Secondary Indications – Paediatric Doses (Off-label):

None established.

RENAL ADJUSTMENT

No dose adjustment required (topical use with minimal systemic absorption).

HEPATIC ADJUSTMENT

Child-Pugh Class	Recommendation
A (Mild)	No adjustment required
B (Moderate)	No adjustment required
C (Severe)	No adjustment required

Not applicable for topical use with minimal systemic absorption.

CONTRAINDICATIONS

• Known hypersensitivity to tetrahydrozoline or any formulation component

• Narrow-angle glaucoma (ophthalmic use)

• Concurrent use of monoamine oxidase inhibitors (nasal use — risk of hypertensive crisis)

• Children below 2 years (without specialist supervision)

CAUTIONS

• Cardiovascular disease including hypertension and arrhythmias

• Hyperthyroidism

• Diabetes mellitus

• Elderly patients — higher risk of systemic effects

• Chronic ocular surface disease — risk of epitheliopathy and rebound redness

• Prolonged nasal use — risk of rhinitis medicamentosa

• Avoid contact of dropper tip with conjunctiva or nasal mucosa (contamination risk)

PREGNANCY

Parameter	Recommendation
Safety category	Limited data; likely low systemic absorption with topical use
Preferred alternatives	Saline drops for nasal congestion
When to use	Only if benefit outweighs risk; short-term use preferred
Monitoring	Observe for systemic absorption symptoms (rare)

LACTATION

Parameter	Recommendation
Compatibility	Likely compatible due to minimal systemic absorption
Drug levels in milk	Expected to be negligible
Preferred alternatives	Saline nasal drops if available
Infant monitoring	Observe for sedation, feeding difficulties (rare)

ELDERLY

• Use lowest feasible frequency (1–2 times daily)

• Increased systemic sensitivity — monitor for bradycardia, lethargy, hypotension

• Avoid chronic or prolonged use due to rebound vasodilation

• Exercise caution in patients with cardiovascular disease

MAJOR DRUG INTERACTIONS

Interacting Drug	Mechanism / Effect	Recommendation
MAO inhibitors (phenelzine, isocarboxazid, tranylcypromine)	Inhibited norepinephrine metabolism → hypertensive crisis	AVOID combination
Tricyclic antidepressants	Additive sympathomimetic effects	Avoid or use with extreme caution

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect	Management
Beta-blockers	Paradoxical blood pressure changes possible	Monitor blood pressure
Other antihypertensives	Hypotension or unpredictable BP response	Monitor closely
Digitalis glycosides	Risk of arrhythmias with systemic absorption	Monitor cardiac rhythm
CNS depressants (in children)	Enhanced sedation or respiratory depression with overdose	Avoid concurrent use; monitor

COMMON ADVERSE EFFECTS

• Ocular burning or stinging (transient)

• Transient blurred vision

• Rebound conjunctival hyperaemia (with prolonged use)

• Nasal dryness and local irritation

• Sneezing (nasal use)

SERIOUS ADVERSE EFFECTS

• CNS depression with overdose — particularly in children (drowsiness, hypothermia, respiratory depression, coma)

• Severe hypertension (nasal form; with excessive use or MAOI interaction)

• Bradycardia or cardiac arrhythmias (systemic absorption)

• Acute angle-closure glaucoma (rare; in predisposed individuals)

• Requires immediate discontinuation and emergency management if systemic toxicity occurs

MONITORING REQUIREMENTS

Phase	Parameters
Baseline	Not routinely required for short-term topical use
After initiation	Assess for local irritation, rebound congestion; observe for systemic symptoms in children
Long-term	Not for chronic use; discourage prolonged or unsupervised application

BRANDS AVAILABLE IN INDIA

• Visine (Ophthalmic drops)

• Murine Plus (Ophthalmic drops)

• Various generics available

• Present as component in multi-ingredient cold formulations

PRICE RANGE (INR)

• Eye/Nasal drops (5–10 mL): ₹25–₹70

• Widely available OTC

• Not under Drug Price Control Order (DPCO); not listed in NLEM

CLINICAL PEARLS

• Counsel patients to avoid prolonged use beyond recommended duration — rebound congestion is common

• Easily accessible OTC; warn against self-treating chronic red eyes without proper diagnosis

• Significant toxicity risk in infants and toddlers from accidental ingestion — emphasise safe storage

• Contraindicated in narrow-angle glaucoma — always check before prescribing for ocular use

• Single-use vials preferred when contamination risk is high (post-surgical patients)

• Consider alternative causes of eye redness (infection, uveitis, glaucoma) before recommending decongestants

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.